Jci_page_head_homepage_01 Jci_page_head_homepage_02
Wanlu Du, Junbo Huang, Hailan Yao, Kechun Zhou, Bo Duan, Yizheng Wang
Published in Volume 120, Issue 10
J Clin Invest. 2010; 120(10):3480–3492 doi:10.1172/JCI43165
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 7
Inhibiting calpain-mediated TRPC6 degradation protected rat brains from ischemic damage.

(A) Immunoblots for TRPC6 and spectrin in the cortical extracts from ischemic or sham-treated rats receiving vehicle or TAT-C6 peptide (TAT-C6). Right panel: quantification of TRPC6 protein levels (n = 3 rats). *P < 0.05 versus vehicle. (B) TTC-stained brain sections indicated the infarct volumes (bar graph) or area (image) in rats receiving vehicle, control TAT-peptide (TAT-ctrl), or TAT-C6 peptide after ischemia (n = 8 rats). *P < 0.05 versus vehicle. (C) Rotarod evaluation of the 2 groups of rats, showing behavioral improvement. Upper curve, rats injected with TAT-C6; lower curve, rats injected with TAT-ctrl. *P < 0.05 versus TAT-ctrl (below, number of rats used for statistical analysis). (D) Survival rates of rats injected with TAT-C6 or TAT-ctrl (n = 6 for TAT-C6 group; n = 10 for TAT-ctrl group) after cerebral ischemia. (E) Immunoblots for CREB and pCREB in the cortical extracts from ischemic or sham-treated rats receiving TAT-ctrl or TAT-C6. Right panel: quantification of pCREB levels (n = 3 rats). **P < 0.01 versus TAT-ctrl. Data are presented as mean ± SEM.